Daconib 45 Mg (Dacomitinib)

Description

Daconib 45 Mg (Dacomitinib) is a prescription medicine used in the treatment of certain types of advanced non-small cell lung cancer (NSCLC). It contains dacomitinib, a targeted medicine that blocks specific signals involved in cancer cell growth. Doctors may prescribe it for patients with certain EGFR gene mutations.

If you are searching for Daconib 45 Mg, understanding its active ingredient, approved use, dosage, precautions, and ordering requirements is important. This page provides general medicine information to help patients and caregivers discuss treatment with their oncology team.

Dacomitinib is not suitable for every person with lung cancer. Its use depends on the cancer type, EGFR mutation status, previous treatment, and the prescriber’s assessment. A prescription and appropriate medical evaluation are required.

OncologyMedi provides access to medicine information and product availability inquiries. Before placing an order, confirm the product name, strength, manufacturer, packaging, and prescription requirements with the pharmacy.

Daconib 45 Mg contains dacomitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It is designed to block signals that help certain cancer cells grow and survive.

The official prescribing information for dacomitinib identifies its use in metastatic NSCLC with specific EGFR mutations. The mutation must be confirmed through an appropriate diagnostic test before treatment is selected.

Key Benefits

Dacomitinib may offer the following treatment-related benefits when prescribed appropriately:

• Targets EGFR signaling in certain cancer cells.
• Provides an oral treatment option for eligible patients.
• Is used as a first-line treatment for specific EGFR-mutated metastatic NSCLC.
• Can be taken with or without food.
• Allows the oncology team to monitor treatment response and adjust therapy when needed.

These benefits describe the medicine’s clinical role. They do not guarantee a particular result for every patient.

Active Ingredient

The active ingredient in Daconib 45 Mg is dacomitinib.

Dacomitinib belongs to a group of medicines called epidermal growth factor receptor tyrosine kinase inhibitors, or EGFR TKIs. These medicines work by blocking certain signals involved in cell growth.

The exact ingredients, tablet appearance, and packaging of Daconib should be confirmed using the product packaging and manufacturer information. Do not rely on tablet appearance alone to verify authenticity.

How Dacomitinib Works

Some non-small cell lung cancers have changes in the EGFR gene. These changes can cause EGFR signaling to remain active, encouraging cancer cells to grow and divide.

Dacomitinib blocks the activity of EGFR and related HER family receptors. This can reduce signaling that supports the growth and survival of certain cancer cells.

The medicine does not work for every lung cancer. Its approved use depends on specific EGFR mutation findings and the patient’s clinical condition.

Dacomitinib is a targeted treatment. It is not a general medicine for cough, chest pain, or breathing problems.

Indications and Uses

Daconib 45 Mg may be prescribed for:

Metastatic non-small cell lung cancer with specific EGFR mutations.

The U.S. prescribing information specifies first-line treatment of metastatic NSCLC with:

• EGFR exon 19 deletion mutations.
• EGFR exon 21 L858R substitution mutations.

An appropriate approved diagnostic test is used to identify eligible patients.

The word “metastatic” means that the cancer has spread to other parts of the body. Your oncologist will determine whether dacomitinib is suitable based on the cancer’s stage, mutation status, and treatment history.

Who May Receive Dacomitinib?

A doctor may consider dacomitinib for a patient who:

• Has a confirmed eligible EGFR mutation.
• Has metastatic NSCLC.
• Is being considered for first-line targeted treatment.
• Has been assessed for the medicine’s risks and benefits.
• Can receive appropriate monitoring during treatment.

Dacomitinib is not automatically appropriate for every person with EGFR-positive lung cancer. Your oncology team will select treatment based on current clinical guidance and your medical history.

Dosage and Administration

The recommended dacomitinib dosage in the official U.S. prescribing information is 45 mg orally once daily. It may be taken with or without food.

Take the medicine at approximately the same time each day, as directed by your prescriber.

The treatment is generally continued until disease progression or unacceptable toxicity occurs. Your doctor may change the dose or stop treatment if side effects become difficult to manage.

How to Take Daconib 45 Mg

1. Take the tablet by mouth at the prescribed time.
2. Swallow it as directed by your pharmacist or doctor.
3. It can be taken with or without food.
4. Try to take it at the same time every day.
5. Follow all instructions on your prescription label.

If you vomit after taking a dose or miss a dose, do not take an extra tablet to make up for it. Follow the prescribing instructions and contact your oncology team if you are unsure what to do.

Available Strengths

Dacomitinib is available in 15 mg, 30 mg, and 45 mg tablet strengths in the referenced U.S. prescribing information.

The availability of Daconib products may vary by manufacturer and country. Confirm the strength and product details with the pharmacy before ordering.

Available Pack Sizes

The available pack size for Daconib 45 Mg should be confirmed from the actual product packaging or manufacturer information.

Oncologymedi should publish the verified pack size, tablet count, and packaging details once confirmed. Do not assume that every market offers the same pack size.

Who Should Not Use This Medicine?

Do not start Daconib 45 Mg without a prescription and medical assessment.

The U.S. prescribing information lists no formal contraindications. However, this does not mean the medicine is suitable for everyone.

Tell your doctor if you:

• Have a history of lung disease or breathing problems.
• Have frequent or severe diarrhea.
• Have significant skin problems.
• Are pregnant or planning pregnancy.
• Are breastfeeding.
• Take medicines for acid reflux or other conditions.
• Have any other medical condition that may affect treatment.

Your doctor will decide whether dacomitinib is appropriate for you.

Warnings and Precautions

Interstitial Lung Disease

Dacomitinib can cause interstitial lung disease (ILD) or pneumonitis, which are serious lung problems. Severe and fatal cases have occurred.

Contact your medical team promptly if you develop new or worsening:

• Shortness of breath.
• Cough.
• Fever.
• Breathing difficulty.

If ILD is confirmed, the prescribing information recommends permanent discontinuation of dacomitinib.

Diarrhea

Diarrhea is one of the most common side effects of dacomitinib. Severe diarrhea can lead to dehydration and other complications.

Tell your doctor if diarrhea develops or becomes worse. Your oncology team may recommend treatment, temporarily withhold the medicine, or reduce the dose depending on severity.

Skin Reactions

Dacomitinib may cause skin reactions, including rash, dry skin, itching, and inflammation around the nails.

Contact your prescriber if you develop persistent or worsening skin symptoms. Dose adjustments may be needed.

Pregnancy and Breastfeeding

Dacomitinib may cause fetal harm.

Patients who can become pregnant should discuss effective contraception with their healthcare provider. The U.S. prescribing information advises contraception during treatment and for 17 days after the last dose.

Breastfeeding is not recommended during treatment and for 17 days after the final dose under the referenced U.S. labeling.

Discuss pregnancy, breastfeeding, and family planning with your oncology team before treatment.

Possible Side Effects

Commonly reported adverse reactions include:

• Diarrhea.
• Rash.
• Paronychia, or inflammation around the nails.
• Stomatitis, or inflammation of the mouth.
• Decreased appetite.
• Dry skin.
• Weight loss.
• Hair loss.
• Cough.
• Itching.

The most common adverse reactions reported in the U.S. prescribing information occurred in more than 20% of patients.

Not every patient experiences these effects. Your doctor or pharmacist can explain which symptoms should be monitored and how they may be managed.

When to Seek Medical Help

Seek prompt medical advice for worsening breathing problems, persistent severe diarrhea, significant skin reactions, or other concerning symptoms.

For severe breathing difficulty or another medical emergency, seek emergency medical care.

Drug Interactions

Dacomitinib can interact with other medicines.

Proton Pump Inhibitors

The U.S. prescribing information recommends avoiding proton pump inhibitors (PPIs) during dacomitinib treatment. PPIs can reduce dacomitinib concentrations.

Examples of acid-reducing medicines include certain treatments for acid reflux and stomach conditions. Ask your doctor or pharmacist before taking any acid-reducing medicine.

H2-Receptor Antagonists

If an H2-receptor antagonist is used, the U.S. label advises taking dacomitinib at least 6 hours before or 10 hours after the H2-receptor antagonist.

CYP2D6 Substrates

Dacomitinib can increase concentrations of medicines that are CYP2D6 substrates. This may increase the risk of toxicity with some medicines.

Tell your prescriber about all medicines, including:

• Prescription medicines.
• Over-the-counter medicines.
• Vitamins.
• Herbal products.
• Medicines taken occasionally.

Do not start or stop a medicine without appropriate medical advice.

Storage Instructions

Follow the storage instructions printed on the product packaging or supplied by the manufacturer.

Keep the medicine:

• In its original packaging.
• Away from children.
• Away from excessive heat and moisture.
• In a safe place where it will not be confused with other medicines.

Do not use damaged, unlabelled, or expired medicine. Contact the pharmacy if the packaging appears unusual or the product information does not match your prescription.

Why Buy From Oncologymedi?

Oncologymedi can build customer confidence by providing clear and verifiable pharmacy information.

Transparent Product Information

Customers should be able to review the generic name, strength, dosage form, manufacturer, and pack size before making an inquiry.

Prescription-Based Ordering

Daconib 45 Mg is a prescription medicine. The pharmacy should explain its prescription verification process and any applicable requirements before completing an order.

Authenticity Information

Customers should receive clear instructions for checking the medicine’s packaging, batch information, and any available manufacturer verification system.

Customer Support

A dedicated pharmacy support channel can help customers confirm product details, availability, and ordering requirements.

Responsible Medicine Access

The pharmacy should provide accurate medicine information and encourage patients to consult their oncology team about treatment decisions.

Authenticity Guarantee

Customers should be encouraged to verify medicine details before use.

Oncologymedi should publish a documented authenticity policy explaining:

• How products are sourced.
• What packaging information customers should check.
• Whether manufacturer verification is available.
• How suspected counterfeit products are handled.
• How customers can contact pharmacy support.

Do not use an “authenticity guaranteed” claim unless the pharmacy can substantiate it through its sourcing and verification procedures.

Prescription Requirements

Daconib 45 Mg is a prescription medicine. It should be used only under the supervision of a qualified healthcare professional.

Before ordering, customers should be prepared to provide the prescription or other documents required by the pharmacy and applicable laws.

The pharmacist may need to confirm:

• Product name and strength.
• Prescribed dose.
• Patient details.
• Prescriber information.
• Prescription validity.
• Delivery destination.

The pharmacy should explain any restrictions before accepting the order.

How to Order Daconib 45 Mg

To inquire about Daconib 45 Mg through Oncologymedi:

1. Review the product name and strength.
2. Confirm that the medicine matches your prescription.
3. Contact the pharmacy to check availability.
4. Ask about the manufacturer and pack size.
5. Submit prescription information if required.
6. Confirm the total cost and delivery details.
7. Follow the pharmacy’s ordering instructions.

Do not place an order for a different strength or medicine without checking with your prescriber.

Conclusion

Daconib 45 Mg (Dacomitinib) is a prescription EGFR-targeted medicine used for certain patients with metastatic non-small cell lung cancer. Its use depends on the appropriate EGFR mutation status and a qualified doctor’s assessment.

Understanding Dacomitinib’s dosage, possible side effects, drug interactions, and prescription requirements helps patients make informed decisions with their oncology team.

If you need Daconib 45 Mg, contact Oncologymedi to check product availability, confirm packaging details, and understand the prescription verification process before ordering.